company background image
IBNSINA logo

IBN SINA Pharmaceutical Industry DSE:IBNSINA Stock Report

Last Price

৳226.10

Market Cap

৳7.1b

7D

-6.5%

1Y

-21.1%

Updated

12 Jun, 2024

Data

Company Financials +

The IBN SINA Pharmaceutical Industry PLC

DSE:IBNSINA Stock Report

Market Cap: ৳7.1b

The IBN SINA Pharmaceutical Industry PLC Competitors

Price History & Performance

Summary of all time highs, changes and price drops for IBN SINA Pharmaceutical Industry
Historical stock prices
Current Share Price৳226.10
52 Week High৳289.70
52 Week Low৳225.00
Beta0.055
1 Month Change-10.21%
3 Month Change-13.17%
1 Year Change-21.11%
3 Year Change-7.90%
5 Year Change-12.36%
Change since IPO6,754.98%

Recent News & Updates

Recent updates

Shareholder Returns

IBNSINABD PharmaceuticalsBD Market
7D-6.5%-4.0%-4.0%
1Y-21.1%-25.4%-27.3%

Return vs Industry: IBNSINA exceeded the BD Pharmaceuticals industry which returned -25.4% over the past year.

Return vs Market: IBNSINA exceeded the BD Market which returned -27.3% over the past year.

Price Volatility

Is IBNSINA's price volatile compared to industry and market?
IBNSINA volatility
IBNSINA Average Weekly Movement2.9%
Pharmaceuticals Industry Average Movement6.7%
Market Average Movement5.2%
10% most volatile stocks in BD Market7.7%
10% least volatile stocks in BD Market3.3%

Stable Share Price: IBNSINA has not had significant price volatility in the past 3 months.

Volatility Over Time: IBNSINA's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19834,000A. K. Sadrul Islamwww.ibnsinapharma.com

The IBN SINA Pharmaceutical Industry PLC produces and sells pharmaceutical drugs in Bangladesh and internationally. The company provides its products in various forms, such as solid dosage forms consisting of tablets and capsules; parenteral products covering ampoules and vials; liquid dosage forms comprising syrups, solutions, suspensions, and powder for suspension (dry syrups); and sterile ophthalmic products, creams, ointments, gels, eye drops and sachet, etc. It also offers various therapeutic products, including analgesic and anti-inflammatory, anti-allergic-occular, anti-arthritis supplement, anti-asthmatic, anti-emetic, anti-fibrinolytic, anti-fungal, anti-glucoma, anti-histamine, anti-malarial, anti-melasma, anti-neuropathic, anti-protozoal, anti-spasmodic, anti-ulcerant, antibacterial, antibiotic, anticataract, anti-diabetic, antigout, anti-helmintic, antimigraine agent, antisecretory, antivertigo agent, and antiviral products. In addition, the company’s therapeutic products comprise antibiotic and steroid, antibiotic-occular, antifungal-occular, antiviral-occular, anxiolytic and antidepressant, aromatase inhibitor, bile acid, bisphosphonates, calcium supplement, cardiovascular preparation, cholinesterase inhibitor, corticosteroid, cough expectorant, dry eye syndrome, gastroprokinetic agent, haematinic/vitamin and mineral, hand rub, hormone products, intestinal anti-inflammatory, laxative, multivitamin and multi-minerals, muscle relaxant, mydriatic agents, nasal decongestant, neuroleptic, nootropic, NSAIDS, NSAIDS-occular, ORS, steroid-occular, topical, urinary incontinence, and sodium-glucose co-transporter inhibitor products.

The IBN SINA Pharmaceutical Industry PLC Fundamentals Summary

How do IBN SINA Pharmaceutical Industry's earnings and revenue compare to its market cap?
IBNSINA fundamental statistics
Market cap৳7.06b
Earnings (TTM)৳689.80m
Revenue (TTM)৳10.87b

10.2x

P/E Ratio

0.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IBNSINA income statement (TTM)
Revenue৳10.87b
Cost of Revenue৳6.41b
Gross Profit৳4.45b
Other Expenses৳3.76b
Earnings৳689.80m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)22.08
Gross Margin40.96%
Net Profit Margin6.35%
Debt/Equity Ratio45.8%

How did IBNSINA perform over the long term?

See historical performance and comparison

Dividends

2.7%

Current Dividend Yield

27%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.